Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2011

Olerup to Distribute Conexio’s SBT HLA Typing Products Worldwide

  • Genomic HLA typing product firm Olerup SSP inked an exclusive five-year global marketing, sales, and distribution agreement with Australia-based Conexio for the latter’s SBT Resolver™-HLA sequencing-based typing (SBT) product line and a version of its Assign™ sequence analysis software. The firms have in addition agreed to co-develop new HLA typing products.

    “This is a big step for us, and we expect the collaboration with Conexio to broaden and strengthen our position on the global HLA typing market with a very competitive SBT solution that complements our current product portfolio,” remarks CEO Olle Olerup, Ph.D.

    Conexio’s SBT Resolver products are locus-specific PCR-based HLA sequencing reagents. Olerup claims the potential market for the SBT technology could match that of its own SSP business. In February the firm appointed Genese Produtos Diagnosticos as the distributor for its SSP HLA genotyping products in Brazil. Olerup claims Brazil represents the world's second largest transplantation market after the U.S., and the firm expects to launch its products in the country during 2011.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »